1-苯并噻吩-5-磺酰氯 | 128852-05-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 1-苯并噻吩-5-磺酰氯
• 中文别名: 苯并[b]噻吩-5-基甲磺酰氯化
• 英文名称: Benzo[b]thiophene-5-sulfonyl chloride
• 英文别名: 1-benzothiophene-5-sulfonyl chloride
• CAS: 128852-05-1
• 化学式: C₈H₅ClO₂S₂
• 分子量: 232.711
• InChiKey: GBTJHYDVNAYQMM-UHFFFAOYSA-N

物化性质

• 沸点：
  369.2±15.0 °C(Predicted)
• 密度：
  1.554±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  70.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-苯并噻吩-5-磺酰氯 在 ammonium hydroxide 作用下， 以 丙酮 为溶剂， 生成 benzo[b]thiophene-5-sulfonamide
  参考文献：
  名称：

  Acyl sulfonamide anti-proliferatives. Part 2: Activity of heterocyclic sulfonamide derivatives

  摘要：

  The anti-proliferative activity of acylated heterocyclic sulfonamides is described in Vascular Endothelial Growth Factor-dependent Human Umbilical Vascular Endothelial Cells (VEGF-HUVEC) and in HCT116 tumor cells in a soft agar diffusion assay. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.11.041
• 作为产物：
  描述：

  5-溴苯并[b]噻吩 在 叔丁基锂 、 二氧化硫 、 N-氯代丁二酰亚胺 作用下， 以 乙醚 、 正戊烷 为溶剂， 生成 1-苯并噻吩-5-磺酰氯
  参考文献：
  名称：

  Acyl sulfonamide anti-proliferatives. Part 2: Activity of heterocyclic sulfonamide derivatives

  摘要：

  The anti-proliferative activity of acylated heterocyclic sulfonamides is described in Vascular Endothelial Growth Factor-dependent Human Umbilical Vascular Endothelial Cells (VEGF-HUVEC) and in HCT116 tumor cells in a soft agar diffusion assay. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.11.041

文献信息

• NOVEL AMINE DERIVATIVE HAVING HUMAN BETA-TRYPTASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：EP1445250A1

  公开（公告）日：2004-08-11

  It is intended to provide a novel low-molecular weight amine derivative, that is absorbed well, has low toxicity, and has an excellent human β-tryptase inhibitory activity with extremely high selectivity, a pharmaceutically acceptable salt thereof, and a medicine containing the same as an active ingredient. The medicine of the present invention is efficacious as a prophylactic/therapeutic agent for diseases in the crisis and evolution of which are considered to be attributed to β-tryptase, for example, respiratory diseases, allergic diseases, inflammatory bowel diseases, hyperprolliferative skin diseases, vascular edema and rheumatoid arthritis.

  本发明旨在提供一种新型低分子量胺衍生物，该衍生物被很好地吸收，毒性低，并且具有极高选择性的优异人类β-色氨酸蛋白酶抑制活性，其药学上可接受的盐，以及含有该衍生物作为活性成分的药物。本发明的药物可作为一种预防/治疗剂，用于被认为是由β-色氨酸蛋白酶引起的危机和发展的疾病，例如呼吸道疾病、过敏性疾病、炎症性肠病、皮肤过度增生疾病、血管水肿和类风湿性关节炎。
• Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13
  作者：Ruben A. Tommasi、Sven Weiler、Leslie W. McQuire、Olivier Rogel、Mark Chambers、Kirk Clark、John Doughty、James Fang、Vishwas Ganu、Jonathan Grob、Ronald Goldberg、Robert Goldstein、Stacey LaVoie、Raviraj Kulathila、William Macchia、Richard Melton、Clayton Springer、Marc Walker、Jing Zhang、Lijuan Zhu、Michael Shultz

  DOI：10.1016/j.bmcl.2011.08.087

  日期：2011.11

  The matrix metalloproteinase enzyme MMP-13 plays a key role in the degradation of type II collagen in cartilage and bone in osteoarthritis (OA). An effective MMP-13 inhibitor would provide a disease modifying therapy for the treatment of arthritis, although this goal still continues to elude the pharmaceutical industry due to issues with safety. Our efforts have resulted in the discovery of a series of hydroxamic acid inhibitors of MMP-13 that do not significantly inhibit MMP-2 (gelatinase-1). MMP-2 has been implicated in the musculoskeletal side effects resulting from pan-MMP inhibition due to findings from spontaneously occurring human MMP-2 deletions. Analysis of the SAR of hundreds of previously prepared hydroxamate based MMP inhibitors lead us to 2-naphthylsulfonamide substituted hydroxamates which exhibited modest selectivity for MMP-13 versus MMP-2. This Letter describes the lead optimization of 1 and identification of inhibitors exhibiting >100-fold selectivity for MMP-13 over MMP-2 (C) 2011 Elsevier Ltd. All rights reserved.
• Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same
  申请人：Kato Yutaka

  公开号：US20050043304A1

  公开（公告）日：2005-02-24

  It is intended to provide a novel low-molecular weight amine derivative, that is absorbed well, has low toxicity, and has an excellent human β-tryptase inhibitory activity with extremely high selectivity, a pharmaceutically acceptable salt thereof, and a medicine containing the same as an active ingredient. The medicine of the present invention is efficacious as a prophylactic/therapeutic agent for diseases in the crisis and evolution of which are considered to be attributed to β-tryptase, for example, respiratory diseases, allergic diseases, inflammatory bowel diseases, hyperprolliferative skin diseases, vascular edema and rheumatoid arthritis.